Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. by Fosså, S. D. et al.
Br.J.Cancer(1990), 61, 639-643 © Macmillan Press Ltd., 1990~~~~~~~~~~~~~~~~~~~~~~~~
Second non-germ cell malignancies after radiotherapy of testicular cancer
with or without chemotherapy
S.D. Fossa', F. Langmark2, N. Aass', A. Andersen2, R. Lothe3 & A.L. B0rresen3
'Department ofMedical Oncology and Radiotherapy, 2The Norwegian Cancer Registry, and 3The Norwegian Cancer Institute, The
Norwegian Radium Hospital, Montebello, N-0310 Oslo 3, Norway.
Summary The incidence of a new primary non-germ cell malignancy was determined in 876 patients with
testicular cancer treated at the Norwegian Radium Hospital from 1956 to 1977. Sixty-five patients developed a
second cancer leading to a statistically significant increased relative risk (RR = 1.58), especially if extended
radiotherapy had been given (RR = 4.13). The excess risks of developing lung cancer and malignant melanoma
were 2.03 and 3.89, respectively. Increased RR for these two cancer types were seen both after extended
radiotherapy and after radiotherapy combined with chemotherapy. Studies of the time between treatment and
secondary lung cancer indicated that the development of the new lung cancer could be partly treatment
related, whereas the raised incidence of malignant melanoma may be related to the frequent health checks
performed in patients with testicular cancer. Patients who had received extended radiotherapy were also at an
increased risk of developing cancer of the stomach and of the colon. Three cases of acute leukaemia were
observed more than 5 years after treatment, all of them in patients who had received abdominal radiotherapy
only. It is concluded that patients apparently cured of a testicular cancer have an increased risk of developing
a new treatment related non-germ cell malignancy, in particular lung cancer. The application of the extended
radiotherapy or the combination of radiotherapy and chemotherapy containing alkylating drugs should be
avoided in order to reduce this excess risk.
Testicular cancer represents 1.25% of all male malignancies
in Norway. Ninety per cent of the patients with testicular
cancer are now cured (Peckham, 1988; Fossa et al., 1988). As
the mean age of patients with this malignancy is about 35
years, most of them will live for 30-40 years after treatment.
The problem of treatment related long-term toxicity has
therefore become important. Some authors have described
organ-related side-effects occurring 5-10 years after radio-
therapy and/or chemotherapy, such as nephrotoxicity, neuro-
toxicity, pulmonary, cardiovascular and gonadal toxicity
(Roth et al., 1988; Fossa et al., 1988; Hansen et al., 1988;
Aass et al., 1990). Four larger series have dealt with the
incidence of second non-germ cell tumours observed after
treatment of testicular cancer (Cockburn et al., 1983; Hay et
al., 1984; Kleinermann et al., 1985; Kaldor et al., 1987). In
these large studies the relation to treatment is, however, not
always considered specifically. The objective of the present
paper is to study the incidence of new non-germ cell malig-
nancies in testicular cancer patients who received
radiotherapy.
Material and methods
Cancer registration and statistical analysis
During the period 1956-1977, 1,484 cases of cancer of the
testis were diagnosed in Norway. Of these patients, 68% had
their primary treatment at the Norwegian Radium Hospital
(NRH). The present study concerns this group of patients.
One hundred and twenty-six patients were excluded because
they had not received standardised radiotherapy. Among
these, chemotherapy had been given to 64 patients, while
most of the remaining 62 patients had no further treatment
after orchidectomy. Two other patients were excluded
because of a malignant tumour before the diagnosis of tes-
ticular cancer. The final series thus consisted of 876 patients.
All new cases of cancer in Norway have been recorded by
the Cancer Registry since 1953. This is based on compulsory
reporting by hospital departments and histopathological
laboratories. All death certificates are coded by the Central
Bureau of Statistics and information about all deaths is
passed on regularly to the Cancer Registry.
From the census in 1960 a personal identification number
has been allocated to all inhabitants of Norway. This number
was used for matching all second primaries. The matching
was automated after 1960 and manual for the preceding
years.
A standard life-table procedure was used to calculate
person years at risk and expected number of cancer cases.
For estimation of the expected number of cancer cases the
5-year age-specific incidence for each of the years 1957-1987
for the whole country was used. The study was based on a
comparison of observed and expected incidence of cancer for
the period 1957-1987 (relative risk (RR): observed/expected
cancer cases). Ninety-five per cent confidence intervals were
determined by assuming a Poisson distribution of the obser-
ved number of cancer cases. A result was regarded as statis-
tically significant if the 95% confidence interval did not
include 1.00.
The follow-up of the patients started 1 year after the date
of diagnosis and all patients were followed up until the end
of 1987 or to the middle of the year of death or emigration.
During the first year after the diagnosis of testicular cancer
none of the 876 patients died, and one cancer case was
observed against 0.1 expected.
The medical records of the 876 patients were reviewed for
diagnostic and treatment details. The differentiation between
seminoma and non-seminoma was based on the routine his-
tological evaluation done by members of the Department of
Pathology at the NRH (Table I). Retrospective staging was
based on the Royal Marsden classification system (Peckham
et al., 1979).
Treatment
Radiotherapy A detailed description of the treatment
principles has been given elsewhere (Fossa et al., 1988).
High-voltage radiotherapy represented the main treatment
modality. Radiotherapy was given by Betatrons 31 or
33 MV (1956-1969) or by linear accelerators (5-8 MV)
(1970-1977). Patients with stage I disease received abdom-
inal radiotherapy. The fields included the bilateral para-aortic
lymph nodes and the ipsilateral iliac lymph nodes (Figure 1).
The daily dose was 2 Gy. Five fractions were given weekly. If
radiotherapy was delivered by Betatrons the iliac lymph
nodes were irradiated by an anterior field only (field size
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approximately 12 x 15 cm), whereas the para-aortic lymph
nodes were covered by a posterior field (field size approx-
imately 12 x 15 cm). Both fields were treated daily. If linear
accelerators were used, radiotherapy was given to an anterior
and posterior abdominal field (L-field) and one field was
treated daily. Seminoma patients were routinely treated with
a total dose of 36-40 Gy; non-seminoma patients received
50 Gy to the abdominal fields. In patients with stage II and
stage III tumours, additional radiotherapy (30-40 Gy) was
given to mediastinal fields, including the left or both supra-
clavicular fossae (Figure 1).
For the purpose of this analysis the mid-plane dose to
the mediastinum from scattered irradiation was estimated.
In patients receiving 40 Gy from a Betatron to standard
abdominal fields, the mediastinal dose was <20 cGy. The
comparable dose in patients treated by a linear accelerator
was 60-70 cGy. In the latter cases the superficial layers
of the skin of the thorax were exposed to a dose of
100- 120 cGy.
Chemotherapy Chemotherapy was given mainly to patients
with stage IV disease or as secondary treatment in case of
relapse.
The type of the cytostatic drugs and of the chemotherapy
regimens has varied during the years. During the first 10
years cyclophosphamide was given as a single drug. During
the years 1966-1975 the Li regimen (Li et al., 1960) and
mithramycin (Klepp et al., 1975) were added to the thera-
peutic armamentarium. From 1975-1977 adriamycin based
combination chemotherapy was the treatment of choice
whenever systemic chemotherapy was considered (Klepp et
al., 1977).
Based on the given treatment, three subgroups of patients
were identified (Table I): Abdominal radiotherapy only (sub-
group 1: 579 patients). These patients received abdominal
radiotherapy only. No secondary treatment was ever applied.
Most of them had seminoma stage I. Abdominal + medias-
tinal radiotherapy (subgroup 2: 87 patients). In these patients
the only therapy was standard abdominal and mediastinal
irradiation. Radiotherapy (any type) + chemotherapy (sub-
group 3: 210 patients). The most often used drugs were
adriamycin and cyclophosphamide. Twenty-three patients
who relapsed after 1977 were treated with cisplatin contain-
ing chemotherapy regimens.
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Figure 1 Routine radiation fields in testicular cancer patients. a,
Betatrons 31/33 MV (1956- 1969); b, linear accelerators (5-8
MV) (1970-1977).
Results
For the total series there was a significantly raised relative
risk for the development of a new non-germ cell cancer (RR:
Table I Patients and treatment
Number
Median agea (years)
Patient years
Sem/non-sem.
Stage I
IV
Radiotherapy
Abd. radioth. (A) alone
A + other fieldsb
A + mediast (M) radioth.
A + M + other fields
Other radioth.
Abdominal rad. dose (Gy)
Infradiafragm.
radioth. only
579
37
9301
394/185
523
49
7
Abdominal +
mediastinal
radioth.
87
39
1087
64/23
12
61
11
3
579
87
Radioth. +
chemoth.
210
32
766
62/149
60
60
30
60
71
28
52
29
30
Total
876
36
11154
519/357
595
170
41
70
650
28
139
29
30
0 43 43
<36 19 2 12 33
36-39 214 18 18 250
40 249 42 70 361
>40 97 25 67 189
Primary chemotherapy
Cyclophosphamide alone 42 42
Adriamycin containing
chemotherapyc 136 136
Other 32 32
aAt orchidectomy. bExcl. mediastinal. CMost often adriamycin + cyclophosphamide +
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1.58), with a statistically significant excess risk for lung
cancer and for malignant melanoma (Table II). In addition,
cancer of the stomach, colon and bladder tended to occur
more frequently than expected. Three cases of leukaemia
were observed against 0.85 expected in the subgroup of
patients with radiotherapy only.
If the different subgroups were considered, lung cancer and
malignant melanoma were again the most frequent new malig-
nancies, but only in patients who had been treated with
extended irradiation or combined radio/chemotherapy. In the
evaluable patients, half of the malignant melanomas were inside
the irradiation field, the others were not. All malignant
melanomas were on the trunk. The RR for lung cancer was also
increased (although not significantly) in patients who only
received abdominal irradiation. There was a higher incidence of
bladder cancer and cancer of the stomach in patients after
abdominal radiotherapy, but this was not statistically significant.
In general, the RR of a solid malignancy was highest 5-14
years after treatment for testicular cancer (Table IV). The
RR for malignant melanoma was highest within years 1-4
and decreased thereafter. Two of the three cases with leu-
kaemia developed 15 years or later after the diagnosis of
testicular cancer. Due to the low number of cases no definite
statement about time dependency can be made for the other
malignancies.
Discussion
In the present study we have not analysed the incidence of
subsequent contralateral testicular germ cell tumours, as
these data are incompletely recorded in the Cancer Registry.
However, other studies have shown that there is an excess
risk of a new primary testicular cancer in patients surviving
their first germ cell cancer (Dieckmann et al., 1986; von der
Maase et al., 1986). These second germ cell tumours prob-
ably develop on the basis of in situ lesions in the remaining
testicle (von der Maase et al., 1986).
This report confirms the increased incidence of new pri-
mary non-germ cell malignancies in patients with testicular
cancer, as also found by Kaldor et al. (1987), Hay et al.
(1984), Kleinermann et al. (1985) and Cockburn et al. (1983).
The incidence of a new cancer was highest within the groups
of patients who received extended radiotherapy or combined
radio/chemotherapy. Such intensive treatment represents a
particular risk factor for second cancer development also
seen in patients cured from Hodgkin's disease (Toland et al.,
1978). However, patients who received radiotherapy alone
also showed an increased risk of second solid malignancies,
especially lung cancer, malignant melanoma and cancer of
the stomach.
We found an excess risk of lung cancer like Hay et al.
(1984) but unlike Kaldor et al. (1987). This increased risk
was most evident 5-14 years after the diagnosis of testicular
cancer. Combined radiotherapy/chemotherapy or extended
irradiation seemed to yield a particularly high risk. The
incidence of lung cancer has been linked epidemiologically to
gamma radiation exposure (Smith & Doll, 1982; Kato &
Schull, 1982). As in these studies, the majority of the lung
Table III Radiotherapy for testicular canceranddevelopment oflung
cancer in 12 patients
Interval
testicular
Radiation dose (Gy) ca to lung
Patient Abdomen Mediast. ca (years) Histology
1 36 8 Large cell ca
2 40 13 Squam. cell ca
3 40 11 Adenoca
4 40 21 Squam. cell ca
5 40 21 Small cell ca
6 40 13 Large cell ca
7 36 32 Carcinomaa
8 40 40 14 Squam. cell ca
9 40 36 14 Squam. cell ca
10 40 40 10 Squam. cell ca
11 36 40 5 Squam. cell ca
12b 50 50 13 Small cell ca
aNot further specified. bIn addition: cyclophosphamide 12.8 g, 5FU
8.2 g, vincristine 23.4 mg, methotrexate 2.2 g, actinomycin C 5.5 mg,
mitramycin 30.8 g.
cancers in our testicular cancer patients were diagnosed
more than 10 years after radiation exposure. This observa-
tion is again in conflict with Kaldor et al. (1987), where the
peak of lung cancer incidence was 5-9 years after radio-
therapy. No firm explanation can be given for these
conflicting observations. Kaldor et al. (1987) did not consider
treatment variations which may have contributed to the
overall result. The results from the present study indicate a
relationship between cytotoxic treatment, especially radio-
therapy, and the incidence of second lung cancer. A similar
relationship has been demonstrated among survivors with
Hodgkin's disease where, as in testicular cancer patients,
large field radiotherapy has played an important therapeutic
role (Kaldor et al., 1987).
A genetic predisposition may account for the increased risk
of a second malignancy in testicular cancer patients. It is
generally believed that cancer develops by multiple steps
resulting in changes in the growth control mechanisms. The
description of genetic events in the development of retino-
blastoma (Cavanee et al., 1983), based on the Knudson
two-hit model (Knudson, 1971), initiated an intense search
for tumour suppressor genes. Loss of specific DNA sequences
in tumour cells have been shown for several familial and
sporadic solid malignancies (Ponder, 1988). Site-specific allele
losses on chromosome 3p have been shown for renal cell
carcinoma and for lung cancer (all types). Sequences on
chromosome lip are lost in Wilms' tumour and bladder
cancer as well as in certain types of lung cancer (Willey et al.,
1988). Recently we have shown that both these regions also
are involved in testicular germ cell tumours (Lothe et al.,
1989).
The fact that both the 3p and lip chromosomal regions
are shown to be involved in lung cancer strengthens the
possibility of a genetic predisposition in a subset of testi-
cular cancer patients who develop lung cancer after treat-
ment. A genetic predisposition may be suggested by features
Table II Treatment and second malignancy
Infradiaphr. Radiotherapy +
radioth. only Infra + Supradiaphr. chemotherapy Total Second 95% confidence
malignancy oa E<b RR 0 E RR 0 E RR 0 E RR interval (total)
Mal. mel. 2 1.52 1.32 3 0.39 7.69** 2 0.09 22.22** 7 1.80 3.89** 1.6-8.0
Leukaemia 3 0.85 3.53 0 0.08 0 0.03 - 3 1.01 2.97 0.6-8.7
Ca bronchus 7 5.01 1.40 4 0.52 7.69** 1 0.26 3.85 12 5.90 2.03** 1.1-3.6
Ca of the stomach 4 3.00 1.75 2 0.24 8.33* 0 0.18 - 6 3.23 1.86 0.7-4.2
Ca coli 3 2.72 1.10 2 0.26 7.69 0 0.08 - 5 3.39 1.47 0.5-3.4
Bladder ca 5 2.49 2.00 0 0.25 - 0 0.07 - 5 2.91 1.71 0.6-4.0
Others 22 19.60 1.12 3 1.87 1.60 2 1.32 1.52 27 23.88 1.13 0.7-1.6
Total 46 34.95 1.32 14 3.39 4.13** 5 2.05 2.44 65 41.13 1.58** 1.2-2.0
aObserved. bExpected. cRelative risk: OIE. *P<0.05; **P<0.01.642 S.D. FOSSA et al.
Table IV Time relationship
Number ofyears after diagnosis oftesticular cancer
1-4 5-14 >
Second malignancy oa E' RRc 0 E RR 0 E RR
Mal. mel. 3 0.30 10.00* 4 0.95 4.21 0 0.56 -
Leukaemia 0 0.18 - 1 0.49 2.04 2 0.33 6.06
Ca bronchus 0 0.64 - 9 2.78 3.24** 3 2.36 1.27
Ca of the stomach 0 0.53 - 5 1.56 3.21 1 1.20 0.83
Ca coli 0 0.36 - 2 1.47 1.36 3 1.35 2.22
Bladder ca 1 0.28 3.57 2 1.34 1.49 2 1.29 1.55
Others 0 3.00 - 18 10.86 1.66 9 9.28 0.97
Total 4 5.29 0.76 41 19.45 2.11** 20 16.37 1.22
aObserved. bExpected. CRelative risk: OIE. *P<0.05; **P<0.01.
like familiar occurrence of testicular neoplasms (Gedde-Dahl
et al., 1985), bilateral tumours and multiple primary malig-
nancies.
The excess risk of malignant melanoma is intriguing.
Radiation exposure within the treatment fields or by scatter-
ed irradiation to the trunk elsewhere may represent one
explanation. However, the highest incidence of malignant
melanoma occurred as early as 1-4 years after the diagnosis
of testicular cancer, making a relationship to treatment
less probable. The increased incidence of malignant mela-
noma is partly due to the increased medical attention during
the frequent follow-up examinations which testicular cancer
patients undergo. As for lung cancer a common predisposing
factor might be present.
Hay et al. (1984) described an excess risk of skin cancer
after the diagnosis of testicular cancer, not distinguishing
between non-melanoma and melanoma. However, from these
authors' discussion it becomes evident that most of the
second skin cancers were non-melanoma registered in
patients who (due to their primary testicular cancer) had
more frequent and intensive health examinations than the
general population.
An increased risk of transitional cell carcinoma in
irradiated sites has been reported previously (Hay et al.,
1984; Kleinermann et al., 1985). This observation is partially
confirmed in the present study by an increased RR of second
bladder cancer, but again the hypothesis of the common
predisposition cannot be rejected.
For the other solid tumour types the numbers are small
and do not allow interpretation. However, in the future the
incidence of a new cancer of the colon and stomach cancer
should be evaluated in larger series. Kaldor et al. (1987)
demonstrated an excess risk of rectal cancer after treatment
for testicular cancer.
Only three cases of leukaemia were observed; all were
acute leukaemia and all three patients had received abdo-
minal radiotherapy as their only treatment. The RR was not
significantly increased as compared to the overall incidence of
leukaemia in the general population. However, for acute
leukaemia there was a significantly increased RR among our
patients. This is in line with observations of Kleinermann et
al. (1985) and Redmann et al. (1984), who found a statis-
tically significant excess risk of acute leukaemia in patients
treated for testicular cancer, after irradiation alone, after
chemotherapy alone or after a combination of both treat-
ment modalities. On the other hand, Hay et al. (1985) did
not find an excess risk of acute leukaemia in irradiated
testicular cancer patients. In the literature it is generally quoted that radiation or chemotherapy induced leukaemia
usually occurs within 2-3 years after completion of treat-
ment. However, in our three patients with acute leukaemia
the malignancy was diagnosed 5 years or more after the
treatment for testicular cancer (more than 15 years after in
two patients). This observation makes any treatment relation
less probable.
The introduction of cisplatin into the treatment of testi-
cular cancer has dramatically changed the treatment policies
in testicular cancer. Non-seminoma patients without metas-
tases no longer receive adjuvant radiotherapy. In testicular
cancer patients with metastases adriamycin or cyclophos-
phamide are used rarely. Cisplatin-based chemotherapy re-
presents the principal therapy. Whether cisplatin-based
chemotherapy increases the risk of secondary cancer is un-
known. Alkylating agents, such as iphosphamide, are, how-
ever, still applied extensively in the modern therapy of both
non-seminoma and seminoma, and abdominal radiotherapy
is still the treatment of choice in low stage seminoma. The
combination of chemotherapy with radiotherapy represents
an actual therapeutic alternative in advanced seminoma. All
these treatment modalities may increase the risk of a second
non-germ cell malignancy in surviving patients.
We feel that the present series allows the following con-
clusions which are still relevant today. 1. The excess risk of a
new non-germ cell cancer in the group of patients with
extended radiotherapy or combined radiotherapy/chemothe-
rapy should lead to reluctance to apply these treatment
modalities routinely in testicular cancer patients, in particular
if alkylating agents and/or adriamycin are applied. Such
combination treatment should only be given if strongly
indicated. 2. Due to a probable excess risk oflung cancer, the
young testicular cancer patient should be warned against
avoidable exposure to known carcinogens. In particular, he
should be strongly advised not to smoke. 3. As our figures
for an increased RR for some new cancers (bladder, stomach,
colon) are only suggestive, and do not yield statistically
significant differences, large co-operative studies are needed
to confirm or disprove the observation. Such studies should
take into account the different treatment modalities.
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